<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119489">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02079870</url>
  </required_header>
  <id_info>
    <org_study_id>NN9535-3685</org_study_id>
    <secondary_id>2013-000012-24</secondary_id>
    <secondary_id>U1111-1138-2039</secondary_id>
    <nct_id>NCT02079870</nct_id>
  </id_info>
  <brief_title>Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo</brief_title>
  <official_title>A Single-centre, Randomised, Double-blind Two-period Cross-over Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of the trial is to investigate the effect of
      semaglutide on energy intake, appetite sensations, postprandial glucose and triglyceride
      metabolism and gastric emptying in obese subjects compared with placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Ad libitum energy intake during a lunch meal (following a standardised breakfast meal)</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean postprandial increase (iAUC15-300min/285 min) in rating of overall appetite score (OAS) using Visual Analogue Scales (VAS) before and up to 300 minutes after intake of a standardised breakfast meal</measure>
    <time_frame>After 12 weeks of treatment during a standardised meal test day</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental area under the 0-300 minutes plasma glucose profile (iAUC0-300min,PG) following intake of a standardised breakfast meal</measure>
    <time_frame>After 12 weeks of treatment during a standardised meal test day</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric emptying measured by the area under the 0-300 minutes plasma paracetamol concentration curve (AUC0-300min,para) following intake of a standardised breakfast meal (including 1500 mg paracetamol)</measure>
    <time_frame>After 12 weeks of treatment during a standardised meal test day</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental area under the 0-480 minutes plasma triglyceride profile (iAUC0-480min,TG) following intake of a standardised fat-rich meal</measure>
    <time_frame>After 12 weeks of treatment during a standardised meal test day</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>From baseline to follow-up (5-7 weeks after last trial drug administration)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <condition>Diabetes</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Sema</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 12-week treatment periods separated by a wash-out period of 5-7 weeks. Finally, a follow-up visit is performed 5-7 weeks after last dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>Solution for subcutaneous (s.c. - under the skin) injection. 0.25 mg semaglutide once weekly for four weeks, 0.5 mg semaglutide once weekly for four weeks followed by 1.0 mg semaglutide once weekly for five weeks</description>
    <arm_group_label>Sema</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Solution for subcutaneous (s.c. - under the skin) injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, age above or equal to 18 years at the time of signing informed
             consent

          -  HbA1c (glycosylated haemoglobin A1c) below 6.5%

          -  A BMI (body mass index) between 30-45 kg/m^2 (both inclusive)

        Exclusion Criteria:

          -  Females who are pregnant, breast-feeding or intend to become pregnant or is of
             childbearing potential and not using adequate contraceptive method (adequate
             contraceptive measures as required by local law or practice, UK requirements:
             adequate contraceptive measures are defined as established use of oral, injected or
             implanted hormonal methods of contraception, sterilisation, intrauterine device or
             intrauterine system, or consistent use of barrier methods together with the use of
             spermicide, and sexual abstinence)

          -  Any disorder which, in the opinion of the investigator, might jeopardise subject's
             safety or compliance with the protocol

          -  Diagnosis of type 1 or 2 diabetes mellitus

          -  Anticipated change in lifestyle (e.g. eating, exercise or sleeping pattern) during
             the trial

          -  Use of any prescription or non-prescription medication which could interfere with
             trial pharmacokinetic or pharmacodynamic results, as judged by the investigator or
             specifically: 1) within 12 months prior to screening any weight lowering
             pharmacotherapy or pharmacotherapy that may cause weight gain, including systemic
             corticosteroids (except for a short course of treatment, i.e., 7-10 days), tri-cyclic
             antidepressants, atypical antipsychotic and mood stabilizers, 2) within 3 months
             prior to screening use of statins, antihyperlipidemics including fibrates or
             nicotinic acid and its derivates, 3) supplementation with omega 3 fatty acids from 1
             month prior to screening, 4) co-treatment with antihypertensive drugs is allowed if
             treatment has been stable for at least 1 month prior to screening and treatment
             should be kept unchanged during the trial

          -  Significant history of alcoholism or drug/chemical abuse within 1 year from
             screening, or a positive result of the urine drug screen or alcohol breath test, or
             consuming more than 21 units of alcohol per week for females and 28 units of alcohol
             per week for males (1 unit of alcohol equals Â½ pint [285 mL] of beer or lager, 1
             glass [125 mL] of wine, or 1/6 gill [25 mL] of spirits)

          -  Smoking or use of any nicotine products (including nicotine patches, gum etc.) in the
             last 3 months prior to screening or a positive cotinine test
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Leeds</city>
        <zip>LS2 9NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 10, 2014</lastchanged_date>
  <firstreceived_date>March 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
